NC
RPRX icon

NewSquare Capital’s Royalty Pharma RPRX Stock Holding History

NewSquare Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-169
Closed -$6.09K – 1012
2025
Q2 		$6.09K Hold
169
– – ﹤0.01% 766
2025
Q1 		$5.26K Hold
169
– – ﹤0.01% 688
2024
Q4 		$4.31K Buy
+169
New +$4.48K ﹤0.01% 386
2023
Q3 		– Sell
-1
Closed -$31 – 840
2023
Q2 		$31 Hold
1
– – ﹤0.01% 828
2023
Q1 		$36 Buy
+1
New +$37 ﹤0.01% 856

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewSquare Capital's RPRX Position: Q3 2025 in Review

NewSquare Capital sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 169 shares — an estimated $6.09K sold.

NewSquare Capital first reported a position in RPRX in Q1 2023 and held it in 5 quarters. The position peaked at $6.09K in Q2 2025. 488 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • NewSquare Capital reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • NewSquare Capital sold 169 Royalty Pharma shares in Q3 2025, an estimated $6.09K.
  • NewSquare Capital first reported a position in Royalty Pharma in Q1 2023 and held it in 5 quarters.
  • NewSquare Capital's Royalty Pharma position peaked at $6.09K in Q2 2025.
  • 488 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on NewSquare Capital's 13F filing for Q3 2025, filed 12 Nov 2025.